Upstream Bio, Inc. (UPB) Stock Profile — Insider Trades & Financials

Revenue$668.0K

Net Income-$42.5M

EPS$-1.88

Market Cap$535.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

E. Sutherland

CEO & Executive Director

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Founded: 2021
Employees: 52
Headquarters: Waltham, Massachusetts, United States
Website

⚡

Core Efficiency

ROE?

-12.50%

ROA?

-12.00%

D/E Ratio?

0.04

Op. Margin?

-6911.23%

📊

Profitability Ratios

Net Margin?

-6356.14%

Loading company sections...

Upstream Bio, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness